An Introduction to Asthma
Asthma is a common and potentially life-threatening chronic inflammatory airway disease. Despite many therapeutic advances, it remains underdiagnosed and undertreated. The mainstay of therapy is maintenance controller therapy such as inhaled corticosteroids, together with separate short-acting β2-agonists for acute symptom relief, but treatment adherence is a major challenge. The heterogeneity of asthma makes it difficult to identify specific therapeutic targets. For patients with specific subtypes of severe asthma, such as eosinophilic asthma, targeted therapies including omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab, can reduce exacerbation rates and improve disease control. As experience with biological therapies increases, they are expected to play a more prominent role in treatment strategies, and novel therapeutic targets such as semaphorins and RhoA/Rho‐kinase, are being investigated.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Richard van Zyl-Smit, ERS 2020 – Optimising Inhaled Therapies for Asthma
Richard van Zyl-Smit (University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa) kindly took the time to speak with us about maximising the benefit of inhaler therapy and recent development being made in this field. Questions What are the major unmet needs in the use of inhaled therapies for the control of […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Liam Heaney, ERS 2020 – Corticosteroid Optimisation using Composite Biomarkers
Following his recent publication in the Lancet Respiratory Medicine, and presentation at the ERS Congress, we spoke with Prof. Liam Heaney (Queen’s University, Belfast, Northern Ireland, UK) about the composite biomarker approach to optimising steroid dosage in patients with severe asthma. Questions Why is there a need for new approaches to optimising steroid dosage in people […]
Kai-Michael Beeh, ERS 2020 – Green Inhalers
Following his presentation at the ERS Congress, Dr. Kai-Michael Beeh (Insaf Respiratory Research Institute, Wiesbaden, Germany) caught up with us to continue the discussion around green inhalers. Questions 1. Could you give us an overview of the environmental impact of asthma inhaler use? (0:22) 2. How do dry powder inhalers compare to metered-dose inhalers in […]
Lavinia Davidescu, EAACI Digital Congress 2020: Severe Asthma without Eosinophilic Markers
TouchRESPIRATORY were lucky to meet with Prof. Lavinia Davidescu (University of Oradea, Romania) to discuss the limitations of the current standard of care for patients with severe asthma patients without eosinophilic markers. Speaker Disclosure: Lavinia Davidescu is the coordinating investigator of masitinib study AB07015 in severe asthma uncontrolled with oral corticosteroids. Support: Interview and filming […]
Lavinia Davidescu, EAACI Digital Congress 2020: Masitinib for Severe Persistent Asthma
Following an excellent presentation at the EAACI Digital Congress 2020, we caught up with Prof. Lavinia Davidescu (University of Oradea, Romania). We discussed the findings from the phase 3 study of masitinib in the treatment of patients with severe persistent asthma (NCT01449162) and what the future holds. Questions 1. Could you tell us a little […]
Severe type 2 asthma: Using biologics to move beyond symptom reduction
Watch leading experts discuss how to identify and manage patients with severe type 2 asthma.
- Identify patients with severe type 2 asthma promptly, including those with co-morbidities
- "Describe the inflammatory pathways that drive type 2 asthma and are targeted by biologic therapies "
- Summarize the data supporting the use of biologics in patients with type 2 severe asthma, including those with co-morbidities
Foreword–US Respiratory & Pulmonary Diseases. 2019;4(1):6
US Respiratory & Pulmonary Diseases. 2019;4(1):6
I am delighted to welcome you to the winter edition of US Respiratory & Pulmonary Diseases, where you will find a range of topical articles that we hope you find useful and relevant to your day-to-day clinical practice. We would like to take the opportunity to invite you to contribute to our winter 2020 edition. […]
Inhaled Corticosteroid Therapy—The Impact of Formulary Changes on Asthma Control
US Respiratory & Pulmonary Diseases. 2019;4(1):10–11
Q. Why did Medicaid discontinue coverage of beclomethasone dipropionate in favor of mometasone furoate? A definitive reason for the change has not been divulged. Most formulary changes of this nature are done for economic reasons, the plan being able to acquire one drug at a lesser cost than another. These changes are quite common with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!